ate AD, and severe AD using Western blotting. Results: Analysis found that 98-kDa GSAP levels were increased, while those of 16 kDa were reduced in the frontal cortex of severe-AD subjects. By contrast, GSAP levels remained stable in the hippocampus. Frontal cortex and hippocampal GSAP 98-and 16-kDa levels were not associated with Aβ, NFT, and neuropathological criteria across clinical groups. Interestingly, only neocortical 98-kDa GSAP values showed a significant correlation with the Mini-Mental State Examination and episodic memory scores. Conclusions: These data demonstrate that GSAP proteins are differentially dysregulated in severe AD, but only the full-length form was associated with cognitive test scores in AD.
ment (APP-CTF) to produce Aβ species. Several endogenous proteins have been reported to selectively modulate Aβ production [2] [3] [4] , including the γ-secretase activating protein (GSAP) [5] . GSAP is synthetized from a larger 98-kDa protein, previously termed the pion homolog protein (PION), which is rapidly processed into the predominant 16-kDa active form [5] , resulting in the modulation of γ-secretase-Aβ production by its interaction with presenilin 1 (PS1) and APP-CTF without affecting notch cleavage [5] . In vitro and in vivo studies have demonstrated that changes in GSAP levels regulate Aβ production [5] [6] [7] . Studies in transgenic mouse models of AD have shown that pharmacological (using the kinase inhibitor imatinib) or genetic reduction of GSAP leads to a decrease in Aβ production, plaque development, and tau phosphorylation [5] [6] [7] . GSAP immunoreactivity has been associated with neuronal PS1 and Aβ immunopositive plaques in the frontal cortex and hippocampus in AD [8] . Frontal cortex GSAP levels are significantly increased in patients with Down syndrome compared to agematched controls [9] . These findings suggest GSAP as a key enzyme in the synthesis of Aβ and, unlike the pharmacological inhibition of γ-secretase, GSAP represents a more selective target for a safer anti-Aβ therapy. Despite its therapeutic potential, whether GSAP levels are altered early in the progression of AD remains unknown. In the present study, we examined protein levels of the fulllength or precursor (98 kDa) and the active form (16 kDa) of GSAP in the frontal cortex and hippocampus, in subjects who died with a premortem diagnosis of noncognitive impairment (NCI), mild cognitive impaired (MCI), mild to moderate AD (mAD) and severe AD (sAD). These data were correlated with cognitive and neuropathological criteria.
Methods

Subjects
Frontal cortex (Brodmann area 10) and hippocampal tissue samples were obtained from European American descendants who died with a premortem clinical diagnosis of NCI ( n = 14), MCI ( n = 5 amnestic MCI and n = 11 nonamnestic MCI), and mAD ( n = 13) from the Rush Religious Orders Study (RROS). Additional cases with a clinical diagnosis of sAD ( n = 13) were examined from the Rush Alzheimer's Disease Center (RADC). Human Research Committees of Rush University Medical Center approved this study.
Clinical and Pathological Analysis
Clinical evaluation included the Mini-Mental State Examination (MMSE), episodic memory, semantic memory, working memory, perceptual speed, visuospatial, and global cognitive scores (GCS), as reported previously [10, 11] . The average time from the last clinical evaluation to death was approximately 8 months. Braak staging [12] , the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) [13] , and the National Institute on Aging (NIA)-Reagan [14] criteria were applied to the RROS subjects as described elsewhere [10, 11, 15, 16] . Five MCI cases were amnestic MCI. Cases with other pathologies (e.g., stroke, Parkinson disease, Lewy body or vascular dementia, and hippocampal sclerosis) were excluded. Clinical, demographic, and neuropathological characteristics of the NCI, MCI, and mAD RROS cases are presented in Table 1 .
A board-certified neuropathologist or trained technician blinded to all clinical data counted the total number of neuritic plaques, diffuse plaques, and neurofibrillary tangles (NFTs) in a 1-mm 2 area (100× magnification) per cortical region from the RROS cases examined [15, 17, 18] . Bielschowsky stain was used to visualize and count neuritic plaques, diffuse plaques, and NFTs. Immunohistochemistry using an antibody against Aβ (4G8, 1: 9,000; Covance, Madison, WI, USA) was used to visualize and measure Aβ density as previously described [19] . The samples from the RADC were evaluated only for NFTs using thioflavin-S to determine Braak staging.
Quantitative Immunoblotting
Frontal cortex and hippocampal tissue samples were dissected free of white matter on dry ice and frozen at -80 ° C. Samples were homogenized (150 mg/mL) in a phosphate buffer containing protease inhibitors (Sigma, St. Louis, MO, USA). A rabbit polyclonal antibody against the C-terminal amino acids 536-565 of human PION was used to detect the full-length 98-kDa and the active 16-kDa GSAP forms (1: 500, Abcam ab113024, Cambridge, MA, USA). Loading control was a β-tubulin antibody (1: 1000; Millipore, Billerica, MA, USA) [15, 20] .
Briefly, proteins were denatured in an SDS loading buffer to a final concentration of 5 mg/mL. Proteins (50 μg/sample) were separated by 4-20% SDS-PAGE (Lonza, Rockland, ME, USA) and electrophoretically transferred to polyvinylidene fluoride membranes (Immobilon P; Millipore) [20] . Membranes were blocked in Tris-buffered saline/0.05% Tween-20/5% milk for 1 h at room temperature. GSAP antibody was added to the blocking buffer and membranes were incubated overnight (4 ° C), washed, and incubated at room temperature (1 h) with horseradish peroxidase-conjugated goat anti-mouse IgG secondary antibody (1: 8,000; BioRad, Hercules, CA, USA) or goat anti-rabbit IgG secondary antibody (1: 5,000; Bio-Rad). The membranes were visualized by chemiluminescence on a Kodak Image Station 440CF (Perkin-Elmer, Wellesley, MA, USA), and the 98-and 16-kDa GSAP bands were quantified across clinical groups using Kodak 1 optical density (OD) measurements. Protein signals were normalized to β-tubulin and analyzed in 3 independent experiments [20] .
Statistical Analysis
Kruskal-Wallis, Mann-Whitney, and χ 2 tests were used to assess differences across clinical groups, followed by a Dunn post hoc test for multiple comparisons. The Spearman rank test was used to correlate the data. Statistical significance was set at p < 0.05 (2-tailed), and measurements were graphically represented using Sigma Plot 12.5 software. 
Results
Case Demographics RROS cases did not differ by age, gender, education, postmortem interval, or brain weight ( Table 1 ). There were no significant differences in the number of cases carrying the APOE ε4 allele between clinical groups. MMSE, perceptual speed, and GCS were significantly ( p < 0.001) lower in mAD compared to MCI and NCI, while differences between the latter 2 groups did not reach significance. Episodic memory scores were significantly lower for mAD compared to NCI and MCI, while MCI scores were lower than NCI ( p < 0.001). No differences in semantic memory and working memory scores were found across the RROS clinical groups examined. NCI subjects displayed a visuospatial z-score that was significantly higher than the mAD cohort ( p < 0.04). Braak score, CERAD, and NIA-Reagan diagnosis were not significantly different among the RROS clinical groups. Evaluation of Braak scores revealed that 50% of NCI and MCI cases were categorized as stages III-IV, while mAD displayed stages IV-V.
Demographics for sAD cases ( n = 13) revealed an average age at death of 78.46 ± 4.66 years (range 71-86 years), postmortem interval of 5.21 ± 2.41 h (range 2-12 h), brain weight of 1,137.91 ± 150.80 g (range 940-1,375 g), MMSE of 2.54 ± 4.36 (range 0-13), Braak stages of IV-V, and a higher percentage of females (61%). This group lacked the extensive cognitive domain and neuropathological examination described for the RROS cases.
GSAP Frontal Cortex and Hippocampal Protein Levels
Groupwise comparisons for frontal cortex and hippocampal proteins are shown in Table 2 . Significant differences were observed for both GSAP 16-and 98-kDa levels in the frontal cortex ( Fig. 1 a-c) , but not in the hippocampus (see online suppl. Fig. S1A-C ; see www. karger.com/doi/10.1159/000477937 for all online suppl. material). Frontal cortex 16-kDa GSAP levels were significantly decreased in sAD compared to mAD and MCI, but not to NCI ( Fig. 1 a, b ; Kruskal Wallis, p = 0.01). There were no significant differences between the mAD, MCI, and NCI groups. Conversely, frontal cortex 98-kDa GSAP levels were significantly higher in sAD compared to NCI and mAD ( Fig. 1 a, c ; Kruskal Wallis, p = 0.002), but not to the MCI group. The mAD, NCI, and MCI groups were not significantly different from each other. The ratio of frontal cortex 16-to 98-kDa GSAP was significantly lower in sAD compared to the other 3 clinical groups ( Fig. 1 d; Kruskal-Wallis, p < 0.001), while the sAD hippocampal ratio was significantly decreased compared to MCI (see online suppl. Fig. S1D ; Kruskal-Wallis, p = 0.002). A subanalysis comparing cases with low (I-III) and high (IV-V) Braak scores in each clinical group revealed a significant decrease in hippocampal 16-kDa protein levels, but not in 98-kDa lev- 239 els, within the high compared to the low Braak score group (Mann-Whitney, p < 0.05) in NCI, but not in the MCI or mAD groups. However, a comparison across clinical groups using low and high Braak subgroups did not reveal significant differences in hippocampal 16-kDa protein levels (Kruskal-Wallis, p > 0.05). No significant differences in frontal cortex or hippocampal 98-and 16-kDa protein levels were observed between the amnestic and nonamnestic MCI cases (Mann-Whitney, p > 0.05).
Association of GSAP Levels with Clinical and Pathological Variables
Correlation analysis between GSAP proteins and the cognitive measures evaluated across clinical groups are shown in online supplementary Table S1 . Frontal cortex and hippocampal 16-kDa GSAP levels were not associated with Aβ, NFT, cognitive measures, or neuropathological criteria (Spearman correlation, p > 0.05). While cortical 98-kDa GSAP levels were moderately correlated with episodic memory (Spearman correlation, r = -0.51, p = 0.003) and MMSE (Spearman correlation, r = -0.41, p = 0.008) and weakly correlated with GCS (Spearman correlation, r = -0.40, p = 0.02). Hippocampal 98-kDa GSAP levels were only weakly correlated with MMSE values (Spearman correlation, r = -0.40, p = 0.01). Scatterplots of these associations are shown online in supplementary Figure S2 . Furthermore, frontal and hippocampal 16-and 98-kDa GSAP values did not correlate with cognitive measures for MMSE, GCS, and episodic memory in each clinical group ( p > 0.05), whereas hippocampal 16-kDa (Spearman correlation, r = -0.9, p < 0.00001) and 98-kDa (Spearman correlation, r = -0.8, 0.009) protein values were negatively associated with Braak scores in NCI cases.
Discussion
GSAP has been identified as a potential novel therapeutic target for AD based on inhibition of its activity and a reduction of Aβ levels without affecting notch cleavage of γ-secretase [5, 6] . However, virtually nothing is known about brain GSAP protein levels and their association Color version available online with cognition and neuropathology during the onset of AD. Here we report the first evaluation of brain GSAP protein levels derived from tissue obtained from subjects with a premortem clinical diagnosis of NCI, MCI, mAD, and sAD. We found that both the precursor and active forms of GSAP were altered in the frontal cortex but not in the hippocampus during the clinical progression of AD. These findings suggest that GSAP protein levels are affected differently depending upon brain.
In the present study, we found a significant upregulation of full-length (98 kDa) GSAP, which co-occurred with a downregulation of the active form (16 kDa) of this protein in the neocortex in sAD cases. Conversely, a recent report using the frontal cortex from a small number of individuals (7 AD and 4 controls) showed an increase in the levels of the active, but not full-length, GSAP [21] . The discrepancies between these findings and ours may be related to differences in methodologies, study design, and/or cohorts examined. Interestingly, levels of the fulllength (98 kDa) and active (16 kDa) GSAP forms were significantly increased in the frontal cortex of patients with Down syndrome compared to age-matched controls [9] . The discrepancy in 16-kDa GSAP levels between Down syndrome and AD (present findings) could be related to the presence of an extra copy of the APP gene in Down syndrome that might stimulate the expression of GSAP or other confounding components such as transcription factors [9, 21] . Data indicate that formation of the 16-kDa GSAP active form depends on caspase-3 [9] , an apoptotic marker that is elevated and highly expressed in NFTs and plaques, in both human AD and animal models of this disease [22, 23] . Although previous investigations indicate that 16-kDa GSAP levels are associated with Aβ deposition [5, 6] , here we found that GSAP protein levels did not correlate with amyloid and NFT scores either in the frontal cortex or hippocampus across clinical groups. Nevertheless, neocortical full-length GSAP levels did correlate with MMSE and episodic memory, revealing a potential role of the full-length but not the active form of GSAP in cognitive impairment in AD. Interestingly, we found that NCI cases with high, but not low, Braak scores showed a decrease in the level of 16-kDa GSAP in the hippocampus. Moreover, in the NCI cases we found that 16-kDa GSAP levels correlated with Braak pathology, suggesting that the active form of this protein is dysregulated in the hippocampus in elderly individuals with high Braak scores, but without cognitive impairment.
In summary, our findings indicate that protein levels for the full-length and the active forms of GSAP are differentially altered in the frontal cortex compared to the hippocampus during the progression of AD. Neocortical full-length GSAP increases while the active form decreases in sAD, whereas both are preserved in the hippocampus across clinical groups. In vitro and in vivo studies suggest that 16-kDa GSAP inhibition reduces amyloid deposition [5, 6] . However, we found a decrease in 16-kDa and an increase in 98-kDa GSAP in sAD despite high amyloid deposits. Taken together, these findings suggest that GSAP does not play a significant role in Aβ production early in the disease process. Further studies are required to investigate the interaction between the different forms of GSAP, Aβ production, and cognition in AD.
